The long-acting depot antipsychotic drugs

Hospital Medicine

Volumn 64, Issue 10, 2003, Pages 603-608

  Pandarakalam, James Paul ^a  

^a WHISTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPHENAZINE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PIMOZIDE; RISPERIDONE;

AKATHISIA; ATHETOSIS; CHOREA; CHOREOATHETOSIS; CLINICAL TRIAL; CULTURAL ANTHROPOLOGY; DIAGNOSTIC ERROR; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; DYSPHORIA; ETHNOLOGY; ETHNOPHARMACOLOGY; EXTRAPYRAMIDAL SYNDROME; GALACTORRHEA; GENDER; HUMAN; HYPERPROLACTINEMIA; INVOLUNTARY MOVEMENT; LONG TERM CARE; MEDICAL ETHICS; NEGATIVE SYNDROME; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN; DELAYED RELEASE FORMULATION; ETHNIC GROUP; FORECASTING;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; ETHICS, MEDICAL; ETHNIC GROUPS; FORECASTING; HUMANS; PRACTICE GUIDELINES; SCHIZOPHRENIA;

EID: 0642372928     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: 10.12968/hosp.2003.64.10.2327     Document Type: Review

References (48)

1. Adebimpe V (1981) Overview: White norms in psychiatric diagnosis of Black American patients. Am J Psychiatry 138: 279-85
2. Baker FM, Carlo B (1999) Issues in the psychiatric treatment of African Americans. Psychiatr Serv 50(3): 362-8
3. Belanger MC (1985) Long acting neuroleptics: techniques for intramuscular injection. Can Nurse 81(8): 41-4
4. Chouinard G, Annable L, Kropsky M (1978) Pipothiazine in schizophrenia. J Clin Pharmacol 18: 148-54
5. Collazo Y, Tam R, Sramek J, Herrera .T (1996) Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt Sinai J Med 63: 310-13
6. Davies IM, Drummond MF (1990) The economic burden of schizophrenia. Psychiatr Bull 14: 522-5
7. Davies IM, Drummond MF (1994) Economic and schizophrenia: the real cost. Br J Psychiatry 25(suppl): 18-21
8. Delay J, Deniker P, Harl JM (1952) Treatment des etats d'excitation et d'agitation par une methods medicamenteuse derive de Phibernotherapie. Ann Med Psychol 10(pt 2): 267-73
9. Department of Health (2001) Reference guide to consent for examination or treatment (online). Available at http://www.doh.gov.uk/consent/refguide.htm (accessed 16 December 2002)
10. Fenton WS, Blyer CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia-empirical and clinical findings. Schizophr Bull 23: 637-51
11. Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR (1997) Ethnicity and antipsychotic response. Ann Pharmacol 31: 1360-9
12. Gillon R (1986) Philosophical Medical Ethics. Wiley, Chichester
13. Glazer WM, Kane JM (1992) Depot neuroleptic therapy: An unutilized treatment option. J Clin Psychiatry 53: 426-33
14. Guinness EA (1991) Acute psychosis and rapid social change in Swaziland. In: Okpaka SO, ed. Mental Health in Africa and the Americas Today. Chrisolith, Nashville: 53-89
15. Hay J (1995) Complications at site of depot neuroleptics. Br J Psychiatry 32: 893-900
16. Jeste DV, Lindamer MA, Evans J, Lacro JP (1996) Relationship of ethnicity and pharmacology of neuroleptics. Psychopharmacol Bull 32: 243-51
17. Jilek WG, Jilek-Aall L (1970) Transient psychosis in Africans. Psychiatr Clin 3: 337-64
18. Kane JM (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5: 225-75
19. Kane JM (1995) Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Pharmacol 10(3): 65-71
20. Kennedy PF, Hershon HI, McGuire RC (1971) Extra pyramidal disorders after prolonged phenothiazines therapy. Br J Psychiatry 118: 509-18
21. Kumar S, Chittaranjan PN, Andrade N, Krishnamurthy S, Muralidharan N (2001) An open clinical trial with risperidone in chronic schizophrenia. Indian J Psychiatry 43: 243
22. Leff JP, Wing JK (1971) Trial of maintenance therapy in schizophrenia. Br Med J 3: 559-604
23. Lewis P, Rack PH, Vaddadi KS, Allen JJ (1980) Ethnic differences in drug response. Postgrad Med J 56(Suppl. 1): 46-9
24. Lin KM, Anathan J (1982) Physical and ethnic variables in dosages for Asians. Am J Psychiatiy 139: 539-40
25. Lin KM, Finder E (1983) Neuroleptic dosage for Asians. Am J Psychiatry 140: 490-1
26. Lin KM, Shen WW (1991) Pharmacotherapy for Southeast Asian psychiatric patients. J Nerv Ment Dis 179: 346-50
27. Lin KM, Anderson D, Poland RE (1995) Ethnicity and psychopharmacology, bridging the gap. Psychiatr Clin North Am 18: 635-47
28. Lindquist P, Allebeck P (1990) Schizophrenia and crime, a longitudinal follow up study of 644 schizophrenics in Stockholm. Br J Psychiatry 157: 343-50
29. Marland GR, Sharkey V (1999) Depot neuroleptics, schizophrenia and the role of the nurse; Is practice evidence based? J Adv Nurs 30: 1255-62
30. Meltzer HY, Okayili G (1995) Reduction of suicidality during clozapine treatment of neuroleptic resistant schizophrenia: impact on cost-benefit assessment. Am J Psychiatry 52: 183-90
31. Mitchell EW (1999) Does psychiatric disorder affect the likelihood of violent offending? A critique of the major findings. Med Sci Law 39: 23-30
32. National Institute for Clinical Excellence (2002) Guidance on the use of Newer Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance No.43. National Institute for Clinical Excellence, London
33. Nicole L, Lesage A, Lolonde P (1992) Lower incidence and increased male to female ratio in schizophrenia. Br J Psychiatry 161: 556-7
34. Pasamanick B, Scarpitti PR, Dinitz AR (1967) Schizophrenics in the Community. Appleton-Century-Croft, New York: 99
35. Planasky K, Johnson R (1971) The occurrence and characteristics of suicidal preoccupation and acts in schizophrenia. Acta Psychiatr Scand 47(4): 473-83
36. Price N, Glazer WM, Morgenstern H (1985) Race and the use of fluphenazine deaconate. Am J Psychiatry 142: 1491-2
37. Pritchard AP, Mallett J (1992) The Royal Marsden Hospital Manual of Clinical Nursing Procedure. 3rd edn. Blackwell Scientific, London
38. Quaid KA, Fade RR, Vining EP (1990) Informed consent for a prescription drug: Impact of disclosed information on patient understanding and medical outcome. Patient Educ Couns 15: 249-59
39. Ramirez L (1996) Ethnicity and psychopharmacology in Latin America. Mt Sinai J Med 63: 330-1
40. Rice D, Miller L (1996) The economic burden of schizophrenia: conceptual and methodological issues, and cost estimates. In: Moscarelli M, Rupp A, Sartorious N, eds. Handbook of Mental Health Economics & Health Policy. Vol 1: Schizophrenia. John Wiley and Sons, New York: 321-34
41. Siegel SJ, Winey KI, Gur RE et al (2002) Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia. Neuropsychopharmacology 26(6): 817-23
42. Suvisaari JM, Haukka JK, Tanskananen AJ, Lonnqvist JK (1999) Decline in the incidence of schizophrenia in Finnish cohorts born from 1954 to 1965. Arch Gen Psychiatry 56: 733-40
43. Tam E, Engelmann F, Fugeres R (1996) Patterns of violent incidents by patients in a general hospital psychiatric facility. Psychiatry Serv 47: 86-8
44. Taylor C, Lillis C, Le Mone P (1993) Fundamentals of Nursing: The Art and Science of Nursing Care. 2nd edn. JB Lippincott, Philadelphia
45. Tunninger E, Levander S (1996) Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry 169: 618-21
46. Tyrer P, Smith J, Adshead G (1994) Ethical dilemma in drug treatments. Psychiatr Bull 18: 203-4
47. Weiden PJ, Olfson M (1995) Cost of relapse in schizophrenia. Schizophr Bull 21: 419-29
48. Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325-51